Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 23- 52-wk high
- $90.87
- 52-wk low
- $48.27
- Prev close
- $71.77
- Mkt cap
- $5.83B
- Fwd P/E
- 38.6x
- Beta
- 0.55
Smart money
Earnings
Earnings came in $1.09 a share above what analysts expected.
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $211.0M | $164.7M | $272.6M | $360.5M |
| Cost of what it sold | $115.9M | $16.3M | $28.0M | $19.9M |
| Gross profit | $95.1M | $148.4M | $244.5M | $340.6M |
| What it spent | ||||
| Research and development | $100.2M | $133.1M | $100.9M | $99.2M |
| Sales and admin | $84.0M | $96.9M | $86.2M | $80.6M |
| Other operating costs | -$92.2M | — | $11.6M | $11.8M |
| Total operating expenses | $92.1M | $230.0M | $198.6M | $191.6M |
| What was left | ||||
| Operating profit | $3.0M | -$81.6M | $45.9M | $149.0M |
| Interest on debt | $32.6M | $55.2M | $49.0M | $48.5M |
| Profit before tax | -$23.1M | -$139.1M | -$2.5M | $97.5M |
| Tax | -$39.0M | -$4.1M | $347.0K | $14.0M |
| Net profit | $15.9M | -$135.0M | -$2.8M | $83.5M |
| EBITDA | $20.6M | -$71.0M | $62.0M | $161.9M |
Technicals
Price structure
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
Coverage is bullish
Tone of tracked coverage
PTC Therapeutics director Schmertzler disposes of $1.8m in stock By Investing.com
NeutralAug 22PTC Therapeutics (NASDAQ: PTCT) director sells 25,000 shares in 10b5-1 trade
Leans bearishAug 21PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages
BullishAug 21